

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Boill Healthcare Holdings Limited**

**保集健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1246)**

### **DATE OF BOARD MEETING, UPDATE ON PUBLICATION OF AUDITED ANNUAL RESULTS AND DELAY IN DESPATCH OF ANNUAL REPORT**

Reference is made to the announcement (the “**Announcement**”) of Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 30 June 2022 in relation to, among others, (i) the unaudited annual results of the Group for the year ended 31 March 2022; and (ii) the delay in publication of the audited annual results of the Group for the year ended 31 March 2022 (the “**2022 Audited Annual Results**”).

### **DATE OF BOARD MEETING AND UPDATE ON PUBLICATION OF AUDITED ANNUAL RESULTS**

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces that a meeting of the Board (the “**Board Meeting**”) will be held on Friday, 29 July 2022, for the purpose of, among others, considering and approving the 2022 Audited Annual Results and its publication, and considering the payment of a final dividend, if any. The 2022 Audited Annual Results will be published on the websites of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Company upon approval by the Board at the Board Meeting.

### **DELAY IN DESPATCH OF ANNUAL REPORT**

Reference is made to the “Frequently asked questions on the Joint Statement in relation to Results Announcements in light of Travel Restrictions related to the Severe Respiratory Disease associated with a Novel Infectious Agent (Joint Statement) and holding of general meetings” issued by the Stock Exchange and last updated on 8 April 2022.

Given that (i) the Group’s financial reporting and audit process for the 2022 Audited Annual Results had been adversely affected by the COVID-19 pandemic, details of which have been disclosed under the section headed “Delay in Publication of Audited Annual Results” in the Announcement; and (ii) additional time will be required to finalise and bulk print the annual report of the Company for the

year ended 31 March 2022 (the “**2022 Annual Report**”) after the completion of audit on the 2022 Audited Annual Results, the Company currently expects that the 2022 Annual Report will be published on the websites of the Stock Exchange and the Company on or before Thursday, 4 August 2022 and despatched to the shareholders of the Company by Friday, 5 August 2022.

The Company will publish further announcement(s) as and when necessary if there are other material developments in the completion of the audit process or if there is any change of the date of the Board Meeting, the expected publication date of the 2022 Audited Annual Results, and/or the expected despatch date of the 2022 Annual Report.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Boill Healthcare Holdings Limited**  
**Dai Dong Xing**  
*Executive Director and Chairman*

Hong Kong, 19 July 2022

*As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung, Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.*